EON: Enhanced Online News (press release) “These findings demonstrated greater glycemic durability, sustained weight loss and reduced risk of hypoglycemia with BYETTA compared to a sulfonylurea in patients with type 2 diabetes,” said Guntram Schernthaner, M.D., professor of medicine and head ...
Wall Street Journal (press release) The Zydus Group announced a breakthrough in its research efforts with Lipaglyn(TM) (Saroglitazar), a novel drug targeted at treating Diabetic Dyslipidemia or Hypertriglyceridemia in Type II diabetes, not controlled by statins alone. The drug has been ...
Bangladesh News 24 hours A US Food and Drug Administration panel of outside experts reopened one of the biggest drug controversies in recent years on Wednesday at a meeting where they will decide whether to recommend lifting marketing restrictions on GlaxoSmithKline Plc's ...
MedPage Today An FDA panel recommendation to loosen restrictions on the controversial diabetes drug rosiglitazone (Avandia) isn't likely to affect how -- or whether -- doctors prescribe it, according to experts interviewed by MedPage Today. Clinicians are wary not ... and more »
Business Standard The Drug Controller General of India (DCGI) approved Cadila Healthcare to launch Lipaglyn (Saroglitazar), a novel drug targeted at bridging an unmet healthcare need for treating Diabetic Dyslipidemia or Hypertriglyceridemia in Type II diabetes, not ...
RTT News Cadila Healthcare Ltd. said the Drug Controller General of India (DCGI) had approved the launch of Lipaglyn (Saroglitazar), a novel drug targeted at bridgin...
Medscape The panel also considered results from a Cochrane-type systematic review of 28 epidemiologic trials conducted by the FDA, which found that rosiglitazone appeare...
Monthly Prescribing Reference Their analysis supported the study's original findings that the risks of mortality and major adverse cardiac events with Avandia in combination with metformin or sulfonylurea are no different than with a combination of metformin and sulfonylurea ... and more »
